

DETAILED CLAIM LISTING

The following is a detailed listing of all claims that are, or were, pending in the present application. Please amend claim 3 and add new claims 13-15, as set forth in this detailed listing.

1. (Original) An isolated human RL5 polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or the amino acid sequence of 29-213 of SEQ ID NO: 2.

2. (Original) The polypeptide of Claim 1 wherein the polypeptide is consisting of the amino acid sequence of 1-213 of SEQ ID NO: 2 or the amino acid sequence of 29-213 of SEQ ID NO: 2.

3. (Currently Amended) An isolated polynucleotide which is selected from the group consisting of:

(a) a nucleotide sequence encoding the polypeptide ~~defined in Claim 1~~ comprising the amino acid sequence of SEQ ID NO:2, or the amino acid sequence of 29-213 of SEQ ID NO:2;
and

(b) the polynucleotide complementary to the nucleotide sequence of (a).

4. (Original) The polynucleotide of Claim 3 which encodes a polypeptide comprising the amino acid sequence of the amino acid sequence of 29-213 of SEQ ID NO: 2.

5. (Original) The polynucleotide of Claim 3 which is selected from the group consisting of

(a) the nucleotide sequence of 85-639 of SEQ ID NO: 1;

(b) the nucleotide sequence of 1-639 of SEQ ID NO: 1; and

(c) the nucleotide sequence of 1-720 of SEQ ID NO: 1.

6. (Original) A vector containing the polynucleotide of Claim 3.

7. (Original) A genetically engineered host cell comprising the vector of Claim 6.

8. (Original) A method for producing RL5 protein, which comprises:
 - (a) culturing the host cell of Claim 7 under the expression conditions, thereby expressing RL5 protein;
 - (b) isolating RL5 protein from the culture.
9. (Original) An antibody specifically bound with the RL5 polypeptide of Claim 1.
10. (Original) A method for detecting the presence of RL5 protein in a sample comprising contacting the sample with an antibody specifically against RL5 protein, thereby forming an antibody complex, and observing the formation of antibody complex which indicates the presence of RL5 protein in the sample.
11. (Original) A pharmaceutical composition comprising a safe and efficient amount of RL5 antagonist and a pharmaceutically acceptable carrier.
12. (Original) The pharmaceutical composition of Claim 11 wherein the RL5 antagonist is an antibody against RL5 protein or an antisense nucleotide sequence of RL5 gene.
13. (New) The method of Claim 8 wherein the polynucleotide is selected from the group consisting of:
 - (a) the nucleotide sequence of 85-639 of SEQ ID NO: 1;
 - (b) the nucleotide sequence of 1-639 of SEQ ID NO: 1; and
 - (c) the nucleotide sequence of 1-720 of SEQ ID NO: 1.
14. (New) An isolated human RL5 polypeptide wherein the polypeptide is encoded by the polynucleotide of Claim 3.
15. (New) The polypeptide of Claim 14 wherein the polypeptide is encoded by the polynucleotide selected from the group consisting of:
 - (a) the nucleotide sequence of 85-639 of SEQ ID NO: 1;
 - (b) the nucleotide sequence of 1-639 of SEQ ID NO: 1; and
 - (c) the nucleotide sequence of 1-720 of SEQ ID NO: 1.